Fadi Fakhouri News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Fadi Fakhouri, MD, PhD: Pegcetacoplan in Post-Transplant C3 Glomerulopathy and IC-MPGN

Fadi Fakhouri, MD, PhD, discusses the 1-year results of the NOBLE trial examining use of pegcetacoplan in patients with post-transplant C3G or IC-MPGN.

Fadi fakhouriLausanne university hospitalEuropean renal association congressApellis pharmaceuticals incEuropean renal associationApellis pharmaceuticals

Pegcetacoplan Offers Potential Benefit in Post-Transplant C3G, IC-MPGN

The phase 2 NOBLE trial shows pegcetacoplan reduces disease activity in post-transplant C3G and IC-MPGN, with benefits persisting through the 40-week double-blind period.

United statesFadi fakhouriCaroline baumalEuropean renal association congressUniversity of lausanne fadi fakhouriApellis pharmaceuticals incLausanne university hospitalAmerican society of nephrology kidney weekLausanne universityAmerican societyNephrology kidney weekEuropean renal associationApellis pharmaceuticals

Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesLissa pavlukMeredith kayaFadi fakhouriLydia abad franchCaroline baumalExchange commissionApellis pharmaceuticals incSobi investor relations teamEuropean renal associationExchange commission onNational institute of healthEuropean unionNorth americaMiddle eastForward looking statement

Swedish Orphan Biovitrum AB: Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress

Swedish Orphan Biovitrum AB: Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesPrnewswire sobiFadi fakhouriCaroline baumalSobi investor relations teamApellis pharmaceuticals incNational institute of healthEuropean renal associationEuropean unionApellis pharmaceuticalsLydia abad franchMedical affairsChief medical officerGenetics homeAccessed novemberNorth america

Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress

Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesPrnewswire sobiCaroline baumalFadi fakhouriNational institute of healthSobi investor relations teamApellis pharmaceuticals incEuropean unionEuropean renal associationApellis pharmaceuticalsLydia abad franchMedical affairsChief medical officerGenetics homeAccessed novemberNorth america